...these alerts has saved us over $0.5m in lost company wide staff productivity,” said Jasper Zwarts, IT Network Engineer, Boehringer Ingelheim. Every time Boehringer Ingelheim is able to rapidly recover from a fault, it saves literally hundreds of...
...and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS™ family of aesthetic dermatology products for facial wrinkles, scar remediation and lip...
...UK looks set to be the first country in the world to switch Boehringer Ingelheim’s Flomax to non-prescription status for treating benign prostatic hyperplasia (BPH). The Medicines and Healthcare products Regulatory Agency (MHRA) has just started a public...
...Vice President of Business Development at CollaGenex Pharmaceuticals. He previously worked at Skye Pharma, RTP Pharma, Boehringer-Ingelheim, and Mylan Laboratories. He holds a B.S. in Industrial Engineering and an M.B.A. degree from West Virginia...
...EUR 7.4 million. The increase in both periods is primarily due to milestone revenues related to our collaboration with Boehringer Ingelheim in the third quarter of 2008. The operating loss for the first nine months of 2008 amounted to EUR 35.2 million...
...and development within the field of oncology. All trials are named accordingly, as variations on this overall theme. Boehringer Ingelheim The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in...
Background
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for around 95% of sales. This includes prescription medicines and consumer healthcare products.
Timeline
You must have Javascript and Flash version 8+ enabled to see this content.
was said in:
1 hour ago from Medical News Today